Halozyme Therapeutics (NASDAQ:HALO) Releases FY25 Earnings Guidance

Halozyme Therapeutics (NASDAQ:HALO) issued an update on its FY25 earnings guidance on Wednesday morning. The company provided earnings per share (EPS) guidance of $4.95-$5.35 for the period, compared to the consensus estimate of $4.83. The company issued revenue guidance of $1.150-$1.225 billion, compared to the consensus revenue estimate of $1.16 billion. Halozyme Therapeutics also updated its FY24 guidance to $4.00-$4.20 EPS.

Wall Street Analyst Weigh In

HALO has been the subject of a number of recent research reports. JMP Securities increased their target price on Halozyme Therapeutics from $72.00 to $73.00 and gave the company a “market outperform” rating in a research note on Friday, November 1st. Cowen reaffirmed a “buy” rating on shares of Halozyme Therapeutics in a research report on Friday, October 18th. Piper Sandler boosted their target price on shares of Halozyme Therapeutics from $51.00 to $52.00 and gave the stock a “neutral” rating in a research report on Monday, November 4th. JPMorgan Chase & Co. lowered shares of Halozyme Therapeutics from an “overweight” rating to a “neutral” rating and raised their price target for the company from $52.00 to $57.00 in a report on Thursday, September 19th. Finally, HC Wainwright reiterated a “buy” rating and issued a $68.00 price objective on shares of Halozyme Therapeutics in a report on Monday, December 30th. Four analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $61.11.

Halozyme Therapeutics Price Performance

Shares of HALO opened at $51.19 on Wednesday. Halozyme Therapeutics has a 52 week low of $33.15 and a 52 week high of $65.53. The company has a current ratio of 10.36, a quick ratio of 9.15 and a debt-to-equity ratio of 3.32. The firm has a market cap of $6.51 billion, a price-to-earnings ratio of 16.95, a PEG ratio of 0.44 and a beta of 1.24. The stock has a 50 day moving average of $50.10 and a 200-day moving average of $54.00.

Insiders Place Their Bets

In other news, SVP Michael J. Labarre sold 10,000 shares of the company’s stock in a transaction that occurred on Wednesday, October 16th. The stock was sold at an average price of $53.26, for a total transaction of $532,600.00. Following the completion of the transaction, the senior vice president now directly owns 173,756 shares of the company’s stock, valued at approximately $9,254,244.56. This represents a 5.44 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. 2.70% of the stock is currently owned by corporate insiders.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.